- Home
- ACRS vs PROF Comparison
ACRS vs PROF Comparison
Compare ACRS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- PROF
- Stock Information
- Founded
- ACRS 2012
- PROF N/A
- Country
- ACRS United States
- PROF Canada
- Employees
- ACRS N/A
- PROF N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- ACRS Health Care
- PROF Health Care
- Exchange
- ACRS Nasdaq
- PROF Nasdaq
- Market Cap
- ACRS 165.7M
- PROF 149.7M
- IPO Year
- ACRS 2015
- PROF N/A
- Fundamental
- Price
- ACRS $1.45
- PROF $6.38
- Analyst Decision
- ACRS Strong Buy
- PROF Strong Buy
- Analyst Count
- ACRS 8
- PROF 2
- Target Price
- ACRS $9.71
- PROF $11.50
- AVG Volume (30 Days)
- ACRS 755.2K
- PROF 50.0K
- Earning Date
- ACRS 08-06-2025
- PROF 08-07-2025
- Dividend Yield
- ACRS N/A
- PROF N/A
- EPS Growth
- ACRS N/A
- PROF N/A
- EPS
- ACRS N/A
- PROF N/A
- Revenue
- ACRS $17,777,000.00
- PROF $11,862,000.00
- Revenue This Year
- ACRS N/A
- PROF $71.17
- Revenue Next Year
- ACRS $11.77
- PROF $134.25
- P/E Ratio
- ACRS N/A
- PROF N/A
- Revenue Growth
- ACRS N/A
- PROF 75.01
- 52 Week Low
- ACRS $1.05
- PROF $3.90
- 52 Week High
- ACRS $5.17
- PROF $11.42
- Technical
- Relative Strength Index (RSI)
- ACRS 51.96
- PROF 69.47
- Support Level
- ACRS $1.37
- PROF $6.69
- Resistance Level
- ACRS $1.59
- PROF $7.02
- Average True Range (ATR)
- ACRS 0.10
- PROF 0.40
- MACD
- ACRS -0.01
- PROF 0.09
- Stochastic Oscillator
- ACRS 28.57
- PROF 69.53
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.